NDAORALTABLET
Approved
Jul 1944
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Dicumarol is an oral anticoagulant tablet approved in 1944 for preventing and treating thromboembolic disorders. It is a coumarin-based vitamin K antagonist that inhibits clotting factor synthesis. The drug is primarily used in patients requiring long-term anticoagulation therapy.
LOE Approaching
This legacy product faces imminent loss of exclusivity with moderate competitive pressure; commercial teams are likely focused on retention and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching LOE, career opportunities on dicumarol are extremely limited and focused on transition/wind-down activities rather than growth. Professionals considering this product should expect minimal team expansion and focus on legacy brand management or market exit planning.
Brand ManagerProduct Manager
Worked on DICUMAROL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.